TheraPPI completes second closing of pre-seed financing
What's the deal? TheraPPIDealroom has a profile for this one. Try Dealroom →, a preclinical-stage biotech developing protein interaction-modifying drugs, has completed the second closing of its pre-seed financing round. The Swiss-French company will use the proceeds to advance its lead oncology programme targeting the ERK/MyD88 protein interaction in the Ras-MAPK pathway — a signalling cascade hyperactivated in more than 40% of human cancers.
Existing shareholders PULSALYSDealroom has a profile for this one. Try Dealroom → and FONGITDealroom has a profile for this one. Try Dealroom → were joined by new biotech-sector investors. The company also appointed pharma executive Christopher Meyer as board chairperson. Meyer currently serves as head of strategy and operational excellence at Ferring PharmaceuticalsDealroom has a profile for this one. Try Dealroom → and as a board member at ETH Zurich spin-off ATLypheDealroom has a profile for this one. Try Dealroom →.
Why now? The first closing took place in March 2025. TheraPPI's approach runs counter to most of the field: where current Ras-MAPK inhibitors work by blocking the pathway, TheraPPI aims to dysregulate it entirely. The company says this lets it kill cancer cells while bypassing the resistance mechanisms that undercut existing drugs — a persistent problem that has limited the efficacy of blockbuster Ras-MAPK therapies.
TheraPPI operates through two entities: TheraPPI Bioscience SAS in France, founded in 2023, and TheraPPI Bioscience SA in Geneva, founded in 2024.
What could go wrong? The company is still at the preclinical stage, meaning years of development and regulatory hurdles lie ahead before any drug reaches patients. Dysregulating rather than blocking a major cancer pathway is scientifically bold but unproven — the approach will need to demonstrate both efficacy and safety in trials. Pre-seed capital also only stretches so far; TheraPPI will likely need larger rounds to fund clinical development.
The signal: TheraPPI's backing from FONGIT, a government and non-profit investor, alongside PULSALYS, an investment fund, illustrates a familiar early-stage biotech playbook in which public and institutional capital de-risks novel science before commercial investors step in. The appointment of a Ferring Pharmaceuticals executive as board chair suggests the company is already positioning for the larger seed or Series A round it will need to reach clinical development.
Read more: Startupticker
